Sarepta competitor files with FDA for Duchenne drug

Sarepta competitor files with FDA for Duchenne drug

Source: 
Seeking Alpha
snippet: 

Sarepta Therapeutics (NASDAQ:SRPT) -3% pre-market after Japanese drugmaker NS Pharma said it filed with the U.S. Food and Drug Administration to seek approval for its new drug to treat Duchenne muscular dystrophy.